Review



iu il 2  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 96
      Buy from Supplier

    Structured Review

    R&D Systems iu il 2
    Iu Il 2, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 812 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/iu+il+2/pmc13103101-251-48-50?v=R%26D+Systems
    Average 96 stars, based on 812 article reviews
    iu il 2 - by Bioz Stars, 2026-07
    96/100 stars

    Images



    Similar Products

    iu il 2  (R&D Systems)
    96
    R&D Systems iu il 2
    Iu Il 2, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/iu+il+2/pmc13103101-251-48-50?v=R%26D+Systems
    Average 96 stars, based on 1 article reviews
    iu il 2 - by Bioz Stars, 2026-07
    96/100 stars
    		  Buy from Supplier
    iu il 2  (Novartis)
    86
    Novartis iu il 2
    CliniMACS Prodigy-manufactured BDCA2 CAR NK cells strongly inhibit tumor growth in vivo when supplemented with exogenous <t>IL-2.</t> (A) On day -7, NSG mice received 5x10 5 RS4;11/BDCA2 cells intravenously. On day 0, mice were intravenously injected with 1x10 7 CAR NK cells or an equivalent number of UTD NK cells. Subcutaneous injections of IL-2 (25,000 U/day) were given to indicated mouse groups from day -1 to day 8. Tumor growth was monitored every two to three days using bioluminescence imaging (BLI). Total flux (B) and representative BLI images (C) were recorded. Data are represented as mean ± SD. Statistical significance was analyzed by two-way ANOVA. **** p < 0.0001; ns: p > 0.05.
    Iu Il 2, supplied by Novartis, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/iu+il+2/pmc12982444-74-21-25?v=Novartis
    Average 86 stars, based on 1 article reviews
    iu il 2 - by Bioz Stars, 2026-07
    86/100 stars
    		  Buy from Supplier
    texmacs gmp complete medium with il-2 supplement (200 iu/ml) media bag  (Terumo BCT)
    90
    Terumo BCT texmacs gmp complete medium with il-2 supplement (200 iu/ml) media bag
    CliniMACS Prodigy-manufactured BDCA2 CAR NK cells strongly inhibit tumor growth in vivo when supplemented with exogenous <t>IL-2.</t> (A) On day -7, NSG mice received 5x10 5 RS4;11/BDCA2 cells intravenously. On day 0, mice were intravenously injected with 1x10 7 CAR NK cells or an equivalent number of UTD NK cells. Subcutaneous injections of IL-2 (25,000 U/day) were given to indicated mouse groups from day -1 to day 8. Tumor growth was monitored every two to three days using bioluminescence imaging (BLI). Total flux (B) and representative BLI images (C) were recorded. Data are represented as mean ± SD. Statistical significance was analyzed by two-way ANOVA. **** p < 0.0001; ns: p > 0.05.
    Texmacs Gmp Complete Medium With Il 2 Supplement (200 Iu/Ml) Media Bag, supplied by Terumo BCT, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/iu+il+2/us12359170-1311-26-43?v=Terumo+BCT
    Average 90 stars, based on 1 article reviews
    texmacs gmp complete medium with il-2 supplement (200 iu/ml) media bag - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier
    iu recombinant human il 2  (R&D Systems)
    96
    R&D Systems iu recombinant human il 2
    CliniMACS Prodigy-manufactured BDCA2 CAR NK cells strongly inhibit tumor growth in vivo when supplemented with exogenous <t>IL-2.</t> (A) On day -7, NSG mice received 5x10 5 RS4;11/BDCA2 cells intravenously. On day 0, mice were intravenously injected with 1x10 7 CAR NK cells or an equivalent number of UTD NK cells. Subcutaneous injections of IL-2 (25,000 U/day) were given to indicated mouse groups from day -1 to day 8. Tumor growth was monitored every two to three days using bioluminescence imaging (BLI). Total flux (B) and representative BLI images (C) were recorded. Data are represented as mean ± SD. Statistical significance was analyzed by two-way ANOVA. **** p < 0.0001; ns: p > 0.05.
    Iu Recombinant Human Il 2, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/iu+il+2/pmc12170346-262-20-24?v=R%26D+Systems
    Average 96 stars, based on 1 article reviews
    iu recombinant human il 2 - by Bioz Stars, 2026-07
    96/100 stars
    		  Buy from Supplier
    il-2 (20 iu/ml; novartis)  (Novartis)
    90
    Novartis il-2 (20 iu/ml; novartis)
    CliniMACS Prodigy-manufactured BDCA2 CAR NK cells strongly inhibit tumor growth in vivo when supplemented with exogenous <t>IL-2.</t> (A) On day -7, NSG mice received 5x10 5 RS4;11/BDCA2 cells intravenously. On day 0, mice were intravenously injected with 1x10 7 CAR NK cells or an equivalent number of UTD NK cells. Subcutaneous injections of IL-2 (25,000 U/day) were given to indicated mouse groups from day -1 to day 8. Tumor growth was monitored every two to three days using bioluminescence imaging (BLI). Total flux (B) and representative BLI images (C) were recorded. Data are represented as mean ± SD. Statistical significance was analyzed by two-way ANOVA. **** p < 0.0001; ns: p > 0.05.
    Il 2 (20 Iu/Ml; Novartis), supplied by Novartis, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/iu+il+2/pmc12082382-163-37-40?v=Novartis
    Average 90 stars, based on 1 article reviews
    il-2 (20 iu/ml; novartis) - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier
    il-2 500 iu/ml proleukin  (Novartis)
    90
    Novartis il-2 500 iu/ml proleukin
    CliniMACS Prodigy-manufactured BDCA2 CAR NK cells strongly inhibit tumor growth in vivo when supplemented with exogenous <t>IL-2.</t> (A) On day -7, NSG mice received 5x10 5 RS4;11/BDCA2 cells intravenously. On day 0, mice were intravenously injected with 1x10 7 CAR NK cells or an equivalent number of UTD NK cells. Subcutaneous injections of IL-2 (25,000 U/day) were given to indicated mouse groups from day -1 to day 8. Tumor growth was monitored every two to three days using bioluminescence imaging (BLI). Total flux (B) and representative BLI images (C) were recorded. Data are represented as mean ± SD. Statistical significance was analyzed by two-way ANOVA. **** p < 0.0001; ns: p > 0.05.
    Il 2 500 Iu/Ml Proleukin, supplied by Novartis, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/iu+il+2/pmc12075070-22-31-30?v=Novartis
    Average 90 stars, based on 1 article reviews
    il-2 500 iu/ml proleukin - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    CliniMACS Prodigy-manufactured BDCA2 CAR NK cells strongly inhibit tumor growth in vivo when supplemented with exogenous IL-2. (A) On day -7, NSG mice received 5x10 5 RS4;11/BDCA2 cells intravenously. On day 0, mice were intravenously injected with 1x10 7 CAR NK cells or an equivalent number of UTD NK cells. Subcutaneous injections of IL-2 (25,000 U/day) were given to indicated mouse groups from day -1 to day 8. Tumor growth was monitored every two to three days using bioluminescence imaging (BLI). Total flux (B) and representative BLI images (C) were recorded. Data are represented as mean ± SD. Statistical significance was analyzed by two-way ANOVA. **** p < 0.0001; ns: p > 0.05.

    Journal: Frontiers in Immunology

    Article Title: Automated manufacturing of clinical-grade BDCA2 CAR NK cells in a closed system for the treatment of blastic plasmacytoid dendritic cell neoplasm

    doi: 10.3389/fimmu.2026.1761397

    Figure Lengend Snippet: CliniMACS Prodigy-manufactured BDCA2 CAR NK cells strongly inhibit tumor growth in vivo when supplemented with exogenous IL-2. (A) On day -7, NSG mice received 5x10 5 RS4;11/BDCA2 cells intravenously. On day 0, mice were intravenously injected with 1x10 7 CAR NK cells or an equivalent number of UTD NK cells. Subcutaneous injections of IL-2 (25,000 U/day) were given to indicated mouse groups from day -1 to day 8. Tumor growth was monitored every two to three days using bioluminescence imaging (BLI). Total flux (B) and representative BLI images (C) were recorded. Data are represented as mean ± SD. Statistical significance was analyzed by two-way ANOVA. **** p < 0.0001; ns: p > 0.05.

    Article Snippet: Two groups of animals, treated with either UTD NK cells or BDCA2 CAR NK cells, received daily subcutaneous injections of 25,000 IU IL-2 (Proleukin S; Novartis Pharma, Nürnberg, Germany), starting one day before (day -1) and continuing through nine days after NK cell treatment (day 8).

    Techniques: In Vivo, Injection, Imaging

    Flow cytometric analysis of the in vivo persistence of tumor cells and NK cells. At the conclusion of the experiment, the persistence of tumor cells (A) , NK cells (B) , and CAR NK cells (C) in the bone marrow, blood and spleen was determined by flow cytometry for mice treated with CAR NK cells with or without exogenous IL-2 support. Data are represented as mean ± SD. Statistical significance was analyzed by two-tailed, unpaired Student’s t-test. **** p < 0.0001; * p < 0.05; ns: p > 0.05.

    Journal: Frontiers in Immunology

    Article Title: Automated manufacturing of clinical-grade BDCA2 CAR NK cells in a closed system for the treatment of blastic plasmacytoid dendritic cell neoplasm

    doi: 10.3389/fimmu.2026.1761397

    Figure Lengend Snippet: Flow cytometric analysis of the in vivo persistence of tumor cells and NK cells. At the conclusion of the experiment, the persistence of tumor cells (A) , NK cells (B) , and CAR NK cells (C) in the bone marrow, blood and spleen was determined by flow cytometry for mice treated with CAR NK cells with or without exogenous IL-2 support. Data are represented as mean ± SD. Statistical significance was analyzed by two-tailed, unpaired Student’s t-test. **** p < 0.0001; * p < 0.05; ns: p > 0.05.

    Article Snippet: Two groups of animals, treated with either UTD NK cells or BDCA2 CAR NK cells, received daily subcutaneous injections of 25,000 IU IL-2 (Proleukin S; Novartis Pharma, Nürnberg, Germany), starting one day before (day -1) and continuing through nine days after NK cell treatment (day 8).

    Techniques: In Vivo, Flow Cytometry, Two Tailed Test